Recombinant Human FVII Protein
$190.00 – $2,600.00
Syd Labs Recombinant Human FVII Protein BP000036-GD10, The potency per mg of recombinant human FVIIa protein was tested and found to be 50,000 Units/mg.
- Product Details
- Description
- Additional information
- More Offers
| Catalog No. | BP000036-GD10 |
|---|---|
| Product Name | Recombinant Human FVII Protein |
| Supplier Name | Syd Labs, Inc. |
| Brand Name | Syd Labs |
| Synonyms | Coagulation Factor VII |
| Source | HEK 293 cell derived. |
| Formulation | Lyophilized from a 0.2 um filtered solution of sodium chloride (2.3 ug/ml), calcium chloride dihydrate (1.5 ug/ml), glycylglycine (1.3 ug/ml), polysorbate 80 (0.1 ug/ml), mannitol (25 ug/ml), sucrose (10 ug/ml), methionine (0.5 ug/ml), and histidine (1.6 ug/ml). pH. 6.0 |
| Purity | > 95%, by SDS-PAGE under reducing conditions and visualized by silver stain. |
| Endotoxin | <1.0 EU per 1 ug of the protein by the LAL method. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Note | Conditions of optimal FVII and FVIIa Proteins performance should be determined experimentally by the investigator. |
| Order Offline | Phone: 1-617-401-8149Fax: 1-617-606-5019Email: message@sydlabs.comOr leave a message with a formal purchaseorder (PO) Or credit card. |
Description
BP000036-GD10: Recombinant Human FVII Protein
Background
Coagulation factor VII (FVII) which is a vitamin K-dependent factor essential for hemostasis. FVII circulates in the blood in a zymogen form, and is converted to an active form (FVIIa) by either factor IXa, factor Xa, factor XIIa, or thrombin by minor proteolysis. Upon activation of the factor VII, a heavy chain containing a catalytic domain and a light chain containing 2 EGF-like domains are generated, and two chains are held together by a disulfide bond. In the presence of factor III and calcium ions, the activated factor (FVIIa) then further activates the coagulation cascade by converting factor IX to factor IXa and/or factor X to factor Xa.
References:
1. Kenet G, et al., 1999, Lancet 354 (9193): 1879.
2. Roberts H, et al., 2004, Blood. 104 (13): 3858-64.
3. Mayer S, et al., 2005, N. Engl. J. Med. 352 (8): 777-85.
4. O’Connell K, et al., 2006, JAMA. 295 (3): 293-8.
Source: HEK 293 cell derived.
Ala21-Pro444, Accession# NP_000122
N-terminal sequence analysis: Ala
Predicted molecular mass: 47 kDa
SDS-PAGE: 57 kDa, reducing conditions
Endotoxin Level: <1.0 EU per 1 ug of the protein by the LAL method. Purity > 95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Formulation: Lyophilized from a 0.2 um filtered solution of sodium chloride (2.3 ug/ml), calcium chloride dihydrate (1.5 ug/ml), glycylglycine (1.3 ug/ml), polysorbate 80 (0.1 ug/ml), mannitol (25 ug/ml), sucrose (10 ug/ml), methionine (0.5 ug/ml), and histidine (1.6 ug/ml). pH. 6.0
Reconstitution: Reconstitute at 100 ug/ml in sterile H2O.
Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month, 2 to 8°C under sterile conditions after reconstitution.
3 months, -20 to -70°C under sterile conditions after reconstitution.
Please remember our product information: Recombinant Human FVII Protein: BP000036-GD10 Syd Labs
Additional information
| Ship from Country | USA |
|---|---|
| Size | 20 ug, 1 mg, 50 ug |